Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 27, 2022
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
[ Thu, Oct 27th 2022
] - WOPRAI
John McNulty Maintained (CC) at Buy with Decreased Target to $41 on, Oct 27th, 2022
John McNulty of BMO Capital, Maintained "The Chemours Company" (CC) at Buy with Decreased Target from $46 to $41 on, Oct 27th, 2022.
John has made no other calls on CC in the last 4 months.
There are 6 other peers that have a rating on CC. Out of the 6 peers that are also analyzing CC, 5 agree with John's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Vincent Andrews of "Morgan Stanley" Maintained at Hold with Decreased Target to $33 on, Tuesday, October 25th, 2022
- Duffy Fischer of "Goldman Sachs" Initiated at Hold and Held Target at $30 on, Thursday, October 13th, 2022
- David Coleman of "Argus Research" Downgraded from Strong Buy to Hold on, Wednesday, October 5th, 2022
- Michael Leithead of "Barclays" Maintained at Hold with Decreased Target to $30 on, Tuesday, September 27th, 2022
- Joshua Spector of "UBS" Maintained at Hold with Increased Target to $37 on, Friday, July 29th, 2022
This is the rating of the analyst that currently disagrees with John
- Arun Viswanathan of "RBC Capital" Maintained at Buy with Decreased Target to $35 on, Thursday, September 22nd, 2022
